Skip to main content
TipRanks
Go Ultimate75% OFF

Ocugen (OCGN) Q3 2026 Earnings Report

6,723 Followers

OCGN Q3 2026 EPS Results

Actual EPS
-$0.01
Consensus EPS
-$0.06
Beat/Miss
Beat by +$0.05
One Year Ago EPS
-$0.07

OCGN Q3 2026 Revenue Results

Actual Revenue
$1.95M
Expected Revenue
$1.32M
Beat/Miss
Beat by +$633.00K
YoY Revenue Growth
+11.36%

Earnings Announcement Details

Quarter
Q3 2026
Date
11/04/2026
Time
Before Open
Conference Call
Wednesday, November 4, 2026
OCGN Upcoming Earnings

Ocugen's next earnings date is estimated for March 10, 2027, based on past reporting schedules.

Q3 2026 Earnings Call Audio

OCGN Q3 2026 Earnings Call
0:00 / 0:00

Q3 2026 Earnings Slide Deck

No slide deck is available for this earnings event.

Q3 2026 Earnings Call Summary

Q3 2026
Earnings Call Date:Nov 04, 2026|% Change Since:2.95%|
Earnings Call Sentiment|Positive

The call was predominantly positive, with Ocugen reporting that all three late-stage programs are in Phase III, completing OCU400 enrollment, initiating OCU410 Phase III treatment, advancing regional licensing and international access, and maintaining a cash runway into 2028. The main challenges were the limited and non-efficacy-focused Stargardt interim analysis, increased operating expenses, and cash coverage for only two of the three programs through anticipated BLA filings.

Company Guidance

Ocugen remains on track to file three BLAs by 2028 and deliver three BLAs over the next three years. OCU400 top-line data are expected in the first quarter of 2027, followed by the planned BLA submission; OCU410ST top-line data are anticipated in the second quarter of 2027, with a BLA submission to follow; and OCU410 is planned to complete trial enrollment in 2027, with a target BLA filing in 2028. The company expects its $84.6 million balance to support its cash runway into 2028, funding two of its three late-stage programs through their anticipated BLA filings. In the Bahamas, OCU400 could receive full approval by the end of the year, with potential patient enrollment as early as year-end, while ArMaDa3 is a 237-subject, one-year trial and the company is currently not planning interim.

  • Three Late-Stage Programs Now in Phase IIIOcugen reported that all three of its late-stage modifier gene therapy programs are now in Phase III: OCU400 for retinitis pigmentosa, OCU410ST for Stargardt disease, and OCU410 for geographic atrophy. The company remains on track to file three BLAs by 2028.
  • OCU400 Phase III Enrollment CompletedEnrollment was completed in the Phase III liMeliGhT trial for OCU400 with 140 patients, randomized to 92 treated and 48 untreated-control subjects. Top-line data are anticipated in the first quarter of 2027, followed by a planned BLA submission.
  • OCU400 Manufacturing Readiness AdvancedProcess performance qualification batches for OCU400 were completed, supporting both the BLA and commercial launch supply.
  • OCU400 Regional Licensing ExpandedOcugen completed an exclusive OCU400 license agreement with Roots Pharmaceutical for the Middle East and North Africa. The agreement provides eligibility for up to $4 million in combined upfront and potential initial development milestone payments, up to $255 million in potential sales milestones, a 22% royalty on net sales, and Ocugen-manufactured commercial supply. This is the company's second regional OCU400 license, following its agreement with Kwangdong Pharmaceutical in South Korea.
  • Bahamas Access Pathway ProgressedOCU400 received provisional approval and priority designation in the Bahamas under the Longevity and Regenerative Therapies Act. Ocugen has executed an agreement with the Global Alliance for Regenerative Medicine to coordinate and manage patient care, is progressing site readiness for full LARTA approval, and is advancing toward potential patient enrollment as early as year-end. The program is open globally, and management stated that pricing would match the U.S. price.
  • OCU400 Early Clinical Data Supported Development PlanIn a post-hoc analysis of seven Phase I/II subjects meeting Phase III eligibility criteria, five of seven treated eyes, or 71.4%, were projected to meet the Phase III responder threshold of at least a two-level improvement on the LDNA scale at week 52. In three-year follow-up, seven of eight evaluable consented treated subjects, or 88%, showed improvement or preservation of LLVA compared with untreated eyes, with no serious adverse events related to OCU400 reported through three years.
  • OCU400 Phase III Statistical PowerManagement stated that the Phase III power analysis estimated 93.2% power even under a hypothetical treatment responder rate of 20% versus 1% in untreated controls. The stated Phase III assumption was 50% improvement in treated eyes versus 10% in controls, which would provide 99% power.
  • OCU410ST Stargardt Program Continued Without ModificationThe independent Data Monitoring Committee recommended continuing the OCU410ST GARDian3 trial without modification. The company remains blinded, is continuing the study through month 12 under the existing protocol, and anticipates top-line data in the second quarter of 2027, followed by a BLA submission.
  • OCU410 Entered Phase IIIThe first patient was dosed in September in ArMaDa3, the global Phase III trial of OCU410 for geographic atrophy. The study plans to enroll 237 subjects, randomized two-to-one to a single subretinal injection of OCU410 or untreated control across the United States, Canada, and Europe. Enrollment is targeted for completion in 2027, with a BLA filing targeted for 2028.
  • Geographic Atrophy Trial Represents First Pivotal Gene Therapy Study in the IndicationManagement stated that ArMaDa3 is the first pivotal gene therapy trial in geographic atrophy. Its primary endpoint is geographic atrophy lesion growth over 12 months, and OCU410 is designed as a single one-time treatment addressing multiple disease pathways.
  • European Presence EstablishedOcugen established a presence in Europe to support development, commercialization, and pre-commercial activities in the region.
  • Cash Runway Extends Into 2028Cash equivalents, restricted cash, and short-term investments totaled $84.6 million as of September 30, 2026. Management expects this balance to support the company's cash runway into 2028 and fund two of its three late-stage programs through their anticipated BLA filings.
  • Quarterly Net Loss Per Share NarrowedOcugen reported a net loss of $0.01 per common share for the three months ended September 30, 2026, compared with a $0.07 loss per share in the prior-year quarter, narrowing the loss by approximately 85.7%.
  • Nine-Month Net Loss Per Share ImprovedFor the nine months ended September 30, 2026, net loss per common share was $0.14 versus $0.17 in the prior-year period, an improvement of approximately 17.6%.

OCGN Earnings History

OCGN earnings history
Report DateFiscal QuarterForecast / EPSLast Year's EPSEPS YoY ChangePress Release
Mar 10, 20272026 (Q4)-0.07--0.06――
Nov 04, 20262026 (Q3)-0.06-0.01-0.0785.71% (+0.06)
Aug 06, 20262026 (Q2)-0.05-0.07-0.05-40.00% (-0.02)
May 05, 20262026 (Q1)-0.05-0.06-0.05-20.00% (-0.01)
Mar 04, 20262025 (Q4)-0.06-0.06-0.05-20.00% (-0.01)
Nov 05, 20252025 (Q3)-0.06-0.07-0.05-40.00% (-0.02)
Aug 01, 20252025 (Q2)-0.06-0.05-0.04-25.00% (-0.01)
May 09, 20252025 (Q1)-0.06-0.05-0.050.00% (+0.00)
Mar 05, 20252024 (Q4)-0.05-0.05-0.03-66.67% (-0.02)
Nov 08, 20242024 (Q3)-0.06-0.05-0.0616.67% (+0.01)

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat Missed